Evaluation and Management of Iron Deficiency in Children Undergoing Intestinal Rehabilitation—A Position Paper From the NASPGHAN Intestinal Rehabilitation Special Interest Group

*Saurabh Talathi, MD, MPH, †Shweta Namjoshi, MD, MPH, ‡Vikram Raghu, MD, MS,
§Danielle Wendel, MD, ¶Stephanie B Oliveira, MD, *Kerry Reed, RN, MS, CPNP-PC,
*Dianna Yanchis, RD, and *Ethan A. Mezoff, MD

ABSTRACT

Iron deficiency (ID) is the most common nutritional deficiency affecting children undergoing intestinal rehabilitation (IR). Patients may be asymptomatic or present with nonspecific symptoms including fatigue, irritability, and dizziness. The diagnosis of ID in this population can be complicated by the coexistence of systemic inflammation or other nutritional deficiencies which may mimic ID. Many routinely available laboratory tests lack specificity and no consensus on screening is available. Success in oral and enteral treatment is impeded by poor tolerance of iron formulations in a population already challenged with intolerance. Newer parenteral iron formulations exhibit excellent safety profiles, but their role in repletion in this population remains unclear. The following report, compiled by a multidisciplinary group of providers caring for children undergoing IR and representing the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Special Interest Group for Intestinal Rehabilitation, seeks to address these challenges. After discussing iron physiology and population-specific pathophysiology, we make recommendations on iron intake, iron status assessment, and evaluation for alternative causes of anemia. We then provide recommendations on iron supplementation and treatment of ID anemia specific to this nutritionally vulnerable population.

Key Words: anemia, intestinal failure, intestinal rehabilitation program, iron deficiency, malnutrition, micronutrient deficiency, nutrition, nutritional deficiencies, parenteral nutrition

(JPGN 2023;76: 672–683)

Iron deficiency (ID) is common in general pediatrics and in children undergoing intestinal rehabilitation (IR), specifically those with intestinal failure (IF) and short bowel syndrome (SBS) (1,2). The documented prevalence of ID in this population ranges from 20% to 87%; Table 1 summarizes the estimated burden (3–8). Low serum iron concentration can be a sign of ID, acute or chronic of Gastroenterology, Hepatology and Nutrition, Nationwide Children’s Hospital, Columbus, OH.

Address correspondence and reprint requests to Saurabh Talathi, MD, MPH, University of Oklahoma Health Science Center – College of Medicine 1200 Children’s Avenue, Suite 14400, Oklahoma City, OK 73104 (e-mail: saurabh.talathi@ouhealth.com).

This article has been developed as a Journal CME and MOC Part II Activity by NASPGHAN. Visit https://learnonline.naspghan.org/ to view instructions, documentation, and the complete necessary steps to receive CME and MOC credits for reading this article.

Disclaimer: NASPGHAN is not responsible for the practices of physicians and provides guidelines and position papers as indicators of best practice only. Diagnosis and treatment is at the discretion of physicians. The authors report no conflicts of interest.

Copyright © 2023 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

DOI: 10.1097/MPG.0000000000003736
TABLE 1. Prevalence of iron deficiency in children undergoing intestinal rehabilitation

<table>
<thead>
<tr>
<th>Study</th>
<th>Study type</th>
<th>Population</th>
<th>Sample size</th>
<th>Prevalence</th>
<th>Study definition of iron deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smith et al(3)</td>
<td>Prospective cohort</td>
<td>Patients aged 0–18 yr requiring home PN for at least 3 mo</td>
<td>15</td>
<td>87%</td>
<td>Unknown</td>
</tr>
<tr>
<td>Ubesie et al(4)</td>
<td>Retrospective cohort</td>
<td>Children with pediatric intestinal failure</td>
<td>178</td>
<td>84% in PN</td>
<td>ID: Serum iron &lt;50 µg/dL or transferrin saturation of &lt;20% or serum ferritin of &lt;30 ng/mL for males and &lt;15 ng/mL for postmenarchal females</td>
</tr>
<tr>
<td>Wu et al(5)</td>
<td>Prospective</td>
<td>Children with neonatal SBS weaned off PN &gt; 2 yr</td>
<td>8</td>
<td>12.5%</td>
<td>ID: Serum iron &lt;6.6 µmol/L per reference laboratory</td>
</tr>
<tr>
<td>Namjoshi et al(6)</td>
<td>Retrospective cohort</td>
<td>Children with IF receiving home PN</td>
<td>59</td>
<td>53%</td>
<td>ID: Iron &lt;23 µg/mL per reference laboratory</td>
</tr>
<tr>
<td>Dahlstrom et al(7)</td>
<td>Prospective</td>
<td>Children (4–65 mo) receiving long term PN</td>
<td>18</td>
<td>33%</td>
<td>ID: comparison of iron serum iron levels to control group IDA: ID with hemoglobin below normal value (&lt;11.1 g/dL)</td>
</tr>
<tr>
<td>Yang et al(8)</td>
<td>Retrospective</td>
<td>Children with severe SBS who were being transitioned from PN to EN</td>
<td>30</td>
<td>20% at PN to EN transition 37% on full EN</td>
<td>IDA: MCV &lt;79 fl and hemoglobin &lt;10.5 g/dL ID: iron value &lt;50 mg/dL</td>
</tr>
</tbody>
</table>

EN = enteral nutrition; ID = iron deficiency; IDA = iron deficiency anemia; IF = intestinal failure; PN = parenteral nutrition; SBS = short bowel syndrome.

Physiology of Iron Absorption in IR

The absorption of iron (Fe) occurs primarily in the proximal small intestine through a process that involves several transport proteins. Iron from dietary sources enters the duodenum and is transported to the ileum via the enterocyte. The initial step in iron absorption is the binding of iron to transferrin in the lumen of the small intestine, which then facilitates the uptake of iron into the enterocyte through the divalent metal transporter 1 (DMT1). Once inside the enterocyte, iron is released from transferrin and binds to ferritin for storage. Iron is then released from ferritin and transported across the basolateral membrane of the enterocyte through the ABC transporter, ABCB11 (the ferroportin protein). The ferroportin is the primary iron exporter in the enterocyte and transports iron into the circulation. Iron transport across the basolateral membrane is regulated by the level of iron stores and the availability of iron for absorption.

Mucosal Transport and Delivery to the Liver

Iron is stored in ferritin, an iron carrier protein, in the cytoplasm of the enterocyte upon absorption across the apical surface of the enterocyte. Some iron is sloughed off into the intestinal lumen with enterocyte turnover, and a portion is delivered to basolaterally located ferroportin 1 (FPN1), the only known iron exporter in the enterocyte. FPN1 is located at the basolateral membrane of the enterocyte and transports iron into the circulation. Iron is then transported by FPN1 to the extracellular fluid where, with the assistance of hephaestin, it is re-oxidized, binds to plasma transferrin, and is transported with transferrin through portal circulation to the liver.

www.jpgn.org
Iron Recycling and Hepatic Storage

Under normal circumstances, iron is not excreted. This is a critically important message for the IR provider to consider when dosing and re-dosing iron. A negligible loss occurs in feces and in urine. Only menstruation, phlebotomy, hemorrhage, and epithelial turnover allow for iron loss from the body. In iron-sufficient individuals, roughly two thirds of total body iron is in red blood cells (RBC) and marrow, almost one third is stored in the hepatocytes and splenic and hepatic macrophages with relatively smaller but functionally important amounts of iron distributed in other tissues (21,23–25). The hepatic reserve is of interest to IR specialists as there is a correlation between iron overload and hepatic fibrosis, infection, and liver transplant waitlist mortality and other liver-related complications (26–33).

Regulation of Absorption by Heparicin

In the setting of negligible iron excretion, iron homeostasis depends on controlling the transfer of dietary iron to the blood plasma by FPN1 and distribution to tissues and body iron stores. To do this, the liver secretes the hormone hepcidin, reducing iron import in the intestine in response to hepatocyte and hepatic sinusoidal endothelial cell iron loading, thus preventing hepatic iron overload. Heparicin binds to FPN1 in the intestine, causing occlusion, internalization, and degradation of this critical receptor (18,23). Just as insulin clears blood glucose, hepcidin clears iron from the bloodstream for about 24 hours. Heparicin is appropriately low in ID, hemorrhage, and hemolysis and is high in chronic kidney disease, rheumatologic disease, infection, and iron refractory iron deficiency anemia. It is inappropriately low in thalassemia and hereditary hemochromatosis (18,23,34,35). All of these disease states can be seen in children undergoing IR, calling for a thoughtful assessment of serum iron concentration.

A low serum iron concentration alone does not indicate total body iron depletion that defines ID, requiring nuanced interpretation of common laboratory assessment based on physiology and anticipated pathophysiology. One study in children with IF failed to associate low iron concentration with anemia (6). Subsequent studies showed that while 1 of 3 of people with IF and anemia did have IDA, about 1 of 3 had anemia of inflammation (26). Of note, when TSAT was above 50% in this population, hemoglobin (Hb) did not increase with parenteral iron loading. Additionally, there was an association between increasing TSAT and hyperbilirubinemia as well as culture positivity (defined as a viral, urine, or blood culture obtained within 6 months of parenteral iron loading) (26).

In a research setting, serum hepcidin is being studied as a potential marker to differentiate ID from these conditions, but is known to be affected by certain factors, including age and circadian rhythm with lowest levels seen during the morning time. In an adult study of 2998 individuals, median serum hepcidin concentration was approximately 7.8 nM/L (22 ng/mL) in men, 4.1 nM/L (11.5 mg/mL) in premenopausal women, and 8.5 nM/L in postmenopausal women (36). Similarly, various assays yield variable reference ranges for serum hepcidin levels, ranging from 1 to 55 ng/mL in healthy individuals (37). In a pediatric study from Korea including 59 children between 5 months to 17 years, serum hepcidin correlated with iron status, with lowest levels seen in children with IDA (2 ng/mL) followed by those with ID without anemia (7.7 ng/mL) followed by those with normal iron levels (16 ng/mL) (38). This study further proposed cut-off points to differentiate IDA (serum hepcidin ≤2.735 ng/mL) from ID (serum hepcidin ≤6.895 ng/mL). In another study of adults with renal dysfunction, the hepcidin index (log[hepcidin]/log[ferritin] ratio) was noted to better predict ID (39).

PATHOPHYSIOLOGY OF IRON DEFICIENCY IN IR

In theory and in practice, ID in children undergoing IR can result from inadequate intake, insufficient absorption at the mucosal surface (heme transporter or DMT1), altered motility, or elevated hepcidin, blocking import at FPN1. It may also occur due to blood loss or turnover through phlebotomy, gastrointestinal (GI) bleeding, or hematologic disease. The circumstances in which these occur in children undergoing IR are illustrated in Figure 1 and described below.

1. Absorption at DMT1: Some children undergoing IR are at risk for IDA due to insufficient intake of iron-rich food. The transition period between weaning PN to a fully enteral diet is an especially high-risk time requiring the monitoring of the intake of iron-rich foods and appropriate use of enteral iron supplementation to prevent or correct IDA. If enteral supplementation or formula is tolerated during this vulnerable time, iron absorption in the duodenum is possible. However, as iron is not routinely present in PN solutions in North America (see iron added to PN below), low daily volumes of oral and enteral feedings and/or intolerance of enteral supplementation can easily result in mismatch of iron availability and need. Rarely, in children who have undergone antrectomy and proximal duodenectomy, iron is unlikely to be absorbed, a situation that would be expected to result in ID (40). It is not known if DMT1 or FPN1 are inducible outside of the proximal duodenum with iron loading. PH-enhanced reductions in iron solubility in the setting of pancreatic insufficiency or gastric acid suppression could contribute to ID, though this has not been demonstrated in a controlled manner.

Pediatric feeding disorder is common in children with IF (41). Some children are limited in their tolerance of meat, iron-rich green vegetables, and seeds. Limited oral acceptance of iron-rich foods increases IDA risk, especially when feeding tubes are not used. Lastly, if high doses of copper, zinc, or calcium are supplemented with iron, there may be competitive absorption at DMT1 among some of these micronutrients (42).

2. Altered motility: If a child has significant gastroparesis, PIPO, or gastrojejunal bypass, with a persistently draining gastroenteric tube, enteral iron might escape into the gastric output (43). Clamping the gastric tube for 30 minutes after enteral iron administration into the gastric port may allow passage into the proximal duodenum for absorption. Likewise, if bowel transit time in a child with SBS is fast, or when the site of maximal iron absorption is bypassed as can be seen with gastrojejunal tubes, enterally supplemented iron may escape into feces. In a case series of children exclusively fed on jejunal feeds, a significant reduction in serum iron and transferrin levels was observed a year after commencing jejunal feeds (44). Another pediatric study of 150 children fed via tube feeding diet reported a 25% reduction in serum ferritin in 25% of children (45). A position paper by the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) expert group on the use of jejunal tube feeding in children recommends that ID should be
assessed in children on jejunal feeds every 6–12 months (46). Enteral iron should not be administered by jejunal route given low evidence for inducible FPN1 expression in the distal small intestine.

3. Decreased iron import at FPN1: Decreased iron import at FPN1 may occur because of high hepcidin concentrations due to a systemic inflammatory state from bowel inflammation, chronic kidney disease, or enteric or systemic infection. Children with dysmotility, bowel transplant rejection, or intestinal graft versus host disease may also have an element of bowel inflammation, leading to elevated hepcidin. Whether or not small bowel bacterial overgrowth (SBBO) leads to increased hepcidin transcription and decreased iron import at FPN1 has yet to be explored. These illnesses characteristically will show the attributes of anemia of inflammation (23,47).

4. Hemorrhage: Bleeding in children undergoing IR occurs with anastomotic ulcers, bowel inflammation, varices, gastric ulcers, serial transverse enteroplasty due to bleeding from staple line, or phlebotomy—as seen in adult as well as neonatal studies (48–53). Anticoagulation used for deep venous thrombosis prophylaxis may also exacerbate hematochezia (54). In these circumstances, in the absence of inflammation, iron is readily absorbed from the GI tract but lost in excess of intake. Hemorrhage may be obvious or, commonly, iron losses may be subclinical, such as in situations of frequent phlebotomy through infancy and early childhood or occult losses from anastomotic ulceration.

5. Prematurity: Healthy term infants are born with sufficient iron stores to meet their iron needs until approximately 6 months of age. From 6 to 24 months of age, iron requirements per kilogram of body weight are higher than during any other period of life because of rapid growth (55). Preterm infants are at increased risk for IDA as iron accumulation is highest in the third trimester (50,56,57). After birth, iron stores in premature infants are depleted in 6–8 weeks, and infants with higher growth velocity deplete tissue iron stores quickly. It is noted that the Hb nadir is lower and occurs earlier in infants with gestational age 28–32 weeks compared to term infants (58). Other conditions such as maternal ID, intrauterine growth restriction, and neonatal or placental blood loss during gestation can increase risk of postnatal IDA. This is exacerbated by surgery or prolonged absence of feeding in children undergoing IR.

6. Adolescence: In adolescence, iron requirements increase due to blood volume expansion, menstruation, and muscle mass increase (42). Iron status in children with SBS and IF should be monitored closely during this time. No recommendation could be provided about the optimal screening interval in adolescents undergoing IR due to lack of supporting evidence and significant variability among author practices.

RECOMMENDED IRON INTAKE AND PREVENTION OF IRON DEFICIENCY IN IR

The U.S. Dietary Reference Intakes include a Recommended Dietary Allowance (RDA) for iron. This refers to the average daily iron intake level sufficient to meet the needs of most healthy individuals in a particular life stage and does not account for pathology-related deficits. Table 2 provides the RDA for iron for term infants and throughout the life cycle. Table 2 provides the RDA for iron for term infants and throughout the life cycle. A preterm infant requires a daily iron intake of 5–6 mg/kg enterally (56–58). In children with gastroparesis, clamping the gastric tube for 30 minutes after enteral iron administration should be considered. It has been suggested that children with IF require more iron than the RDA; maintenance enteral iron doses in IF range between 4 and 6 mg/kg/day and

FIGURE 1. Physiology of iron metabolism and pathophysiology of iron deficiency in children undergoing intestinal rehabilitation.
TABLE 2. Recommended Dietary Allowance (RDA) for iron (mg/day)

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth to 6 mo</td>
<td>0.27 mg*</td>
<td>0.27 mg*</td>
</tr>
<tr>
<td>7–12 mo</td>
<td>11 mg</td>
<td>11 mg</td>
</tr>
<tr>
<td>1–3 yr</td>
<td>7 mg</td>
<td>7 mg</td>
</tr>
<tr>
<td>4–8 yr</td>
<td>10 mg</td>
<td>10 mg</td>
</tr>
<tr>
<td>9–13 yr</td>
<td>8 mg</td>
<td>8 mg</td>
</tr>
<tr>
<td>14–18 yr</td>
<td>11 mg</td>
<td>15 mg</td>
</tr>
</tbody>
</table>

TABLE 3. Laboratory markers commonly used to differentiate ID/IDA from commonly encountered conditions in children undergoing IR

<table>
<thead>
<tr>
<th>Lab test</th>
<th>No ID</th>
<th>ID</th>
<th>IDA</th>
<th>IRIDA</th>
<th>Anemia of inflammation</th>
<th>Vitamin B12 deficiency or folate deficiency anemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>N</td>
<td>N</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>MCV</td>
<td>N/elevated</td>
<td>N/low</td>
<td>Low</td>
<td>Very low</td>
<td>Low to N</td>
<td>Elevated</td>
</tr>
<tr>
<td>Serum iron</td>
<td>N</td>
<td>Low</td>
<td>Low</td>
<td>Very low</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>TIBC</td>
<td>N</td>
<td>N/elevated</td>
<td>Elevated</td>
<td>Elevated</td>
<td>Variable</td>
<td>N</td>
</tr>
<tr>
<td>TSAT</td>
<td>N</td>
<td>N</td>
<td>Low</td>
<td>Very low</td>
<td>Low to N</td>
<td>N</td>
</tr>
<tr>
<td>SF</td>
<td>N</td>
<td>Low</td>
<td>Low</td>
<td>N/elevated</td>
<td>N/elevated</td>
<td>N</td>
</tr>
<tr>
<td>STR*</td>
<td>N</td>
<td>Elevated</td>
<td>Elevated</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Hepcidin</td>
<td>N</td>
<td>Low</td>
<td>Low</td>
<td>Elevated</td>
<td>Elevated</td>
<td>N</td>
</tr>
</tbody>
</table>

*Soluble transferrin receptor can be elevated in patients with hemolysis or with administration of erythropoiesis-stimulating agents.

**Estimates parenteral requirements of iron**

<table>
<thead>
<tr>
<th>Age</th>
<th>Requirement (µg/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preterm</td>
<td>200–250</td>
</tr>
<tr>
<td>0–18 yr</td>
<td>50–100</td>
</tr>
<tr>
<td>Maximum dose</td>
<td>5 mg/day</td>
</tr>
</tbody>
</table>

* Adequate intake—intake at this level is assumed to ensure nutritional adequacy, established when evidence is insufficient to develop an RDA.

**Recommendation:** In children with suspected altered GI motility (gastrosparesis, PIPO) or a history of gastrojejunal bypass, persistently draining G tube, we recommend clamping the G tube for 30 minutes after enteral iron administration into the gastric port for improved absorption into the duodenum. (8 authors in favor)

**ASSESSMENT OF IRON STATUS IN IR**

**Testing for ID**

The gold standard to diagnose IDA is bone marrow biopsy, which is impractical for diagnosis and monitoring. The available options for laboratory testing include measurement of Hb, TSAT, RBC count, serum iron concentration, total iron-binding capacity (TIBC), hematoцит and RBC indices, serum ferritin (SF), soluble transferrin receptor, reticulocyte count, serum hepcidin (in a research setting), zinc protoporphyrin, and a reticulocyte Hb content (1,63). In a survey of almost 400 pediatric hematologists evaluating IDA, more than half obtained a serum iron and TIBC, whereas 30% obtained TSAT, and 70% obtained SF (63). Careful selection of the available tests is important in IR because serum iron and SF are both strongly affected by inflammation, and can be poor indicators of ID in cases of infection or inflammation. Obtaining a C-reactive protein (CRP) when assessing iron status in these children may help distinguish true abnormalities from an acute phase response. Serum iron and TIBC have also been shown to have a diurnal variation, peaking in the morning (64).

**Recommendation:** Screening for ID/IDA in children undergoing IR should not be based on a Hb and mean corpuscular volume (MCV) alone. We recommend screening for IDA based on a complete blood count (CBC), SF, TSAT, serum iron concentration, and TIBC. (8 authors in favor)

**Recommendation:** A CRP should be obtained while screening for ID as SF is an acute phase reactant. (8 authors in favor)

The frequency of iron status monitoring in IR programs varies from every 3–6 months to annually and may depend on whether it is routine screening versus assessment of response to therapy (65). Other nutrition screening varies from every 3–6 months depending on factors including ID risk, nutritional status, enteral tolerance, and stage of rehabilitation. The practice of phlebotomy itself should be re-evaluated in IR, as 1 mL of packed RBC blood loss results in approximately 1 mg of iron loss, so a child with a hematocrit of 40% loses 0.4 mg of iron with each 1 mL of whole blood, or up to 10 mL and 10 mg of iron loss for a basic metabolic panel, magnesium, and phosphorus level depending on the center’s draw technique (66).

**Recommendation:** Children undergoing IR should be screened for ID/IDA. We recommend screening every 3–6 months. (7 authors in favor, 1 opposed)

**Recommendation:** In children with suspected altered GI motility (gastrosparesis, PIPO) or a history of gastrojejunal bypass, persistently draining G tube, we recommend clamping the G tube for 30 minutes after enteral iron administration into the gastric port for improved absorption into the duodenum. (8 authors in favor)

**Recommendation:** In children with suspected altered GI motility (gastrosparesis, PIPO) or a history of gastrojejunal bypass, persistently draining G tube, we recommend clamping the G tube for 30 minutes after enteral iron administration into the gastric port for improved absorption into the duodenum. (8 authors in favor)
Table 3 describes a set of laboratory assessments that can be used to differentiate ID from commonly encountered conditions in children undergoing IR. Patients may have IDA, vitamin B12, and/or folate deficiency with resulting normal MCV. MCV can also be elevated in liver disease, making it an unreliable marker for ID assessment in children with IF-associated liver disease (IFALD). Deficiencies of copper or zinc, or preexisting hemoglobinopathies can lead to microcytosis. Figure 2 describes an algorithm for determining IDA in children undergoing IR based on TSAT and SF. We propose 3 distinct categories: 1. Children without ID; 2. Children with ID without anemia; and 3. Children with IDA (Table 3). Caution should be taken in the assessment of IDA in cases of a suspected infection or inflammation such as central line-associated bloodstream infections, SBBO, childhood viral infections, and other inflammatory conditions. 

Recommendation: Vitamin B12, zinc, and copper deficiency should be evaluated based on anatomic risk and in children not responding to conventional treatment. (7 authors in favor, 1 opposed)

Recommendation: While assessing iron status in children undergoing IR, we recommend categorizing children into 3 categories: 1. Children without ID; 2. Children with ID without anemia; and 3. Children with IDA. This will enable IR providers to make an informed decision regarding treatment. (8 authors in favor)

Screening for Other Conditions Including Thalassemia

Microcytosis is a common finding in carriers of alpha or beta thalassemia. However, anemia is not generally profound in people with thalassemia, and iron parameters are often normal or increased. Screening for thalassemia should be considered in children undergoing IR with features similar to IDA refractory to conventional iron therapy to avoid dangerous hepatic overload (59). This may be especially important in patients with Pacific Islander, Southeast Asian, South Asian, Southwest Asian, or North African ancestry.

Recommendation: Screening for thalassemia should be considered in children not responding to conventional treatment in certain patient populations. (6 authors in favor, 1 opposed and 1 abstained from commenting)

Role of Endoscopy

Since inadequate intake or frequent blood draw are common causes of IDA in the IR population, endoscopy is not routinely required. However, it is appropriate to consider an endoscopy in cases of persistent IDA, or IDA associated with low albumin, low zinc, low vitamin D, elevated CRP, or IDA not responding to enteral treatment. Other conditions that increase the risk of IDA and may require an endoscopy are anastomotic ulcers, and intestinal inflammation.

Recommendation: In the assessment of ID in children undergoing IR, endoscopy is not routinely recommended. It can be considered if there is a poor response to enteral iron or if concerning signs and symptoms suggest GI bleeding, or intestinal inflammation. (6 authors in favor, 1 opposed and 1 abstained)

Referral to a Hematologist

Referral to pediatric hematology involves institution-specific considerations and is often reserved for select cases, such as unresponsiveness to oral and/or parenteral iron therapy, the need for multiple blood transfusions in the absence of a GI cause, or pancytopenia without portal hypertension.

Recommendations: Referral to a hematologist can be reserved for lack of recovery of Hb with iron supplementation, presence of pancytopenia, or difficulty distinguishing between multiple micronutrient deficiencies, portal hypertension, cancer, or other marrow insufficiency. (8 authors in favor)
TABLE 4. Iron formulations available in the United States

<table>
<thead>
<tr>
<th>Iron type</th>
<th>Standard dosing</th>
<th>Formulation(s)</th>
<th>Cost*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral/enteral</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrous sulfate</td>
<td>3–6 mg/kg/day</td>
<td>75 mg/mL (15 mg elemental iron)</td>
<td>$2.58–$6.84 for 473 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>220 mg/5 mL (44 mg elemental iron)</td>
<td>$167.59 for 500 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>300 mg/5 mL (60 mg elemental iron)</td>
<td>$0.69–$2.21 for 100 tablets</td>
</tr>
<tr>
<td></td>
<td></td>
<td>325 mg tablet (65 mg elemental iron)</td>
<td>$5.02–$6.16 for 1000 tablets</td>
</tr>
<tr>
<td>Ferrous fumarate</td>
<td>3–6 mg/kg/day</td>
<td>324 mg tablet (106 mg elemental iron)</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td>325 mg tablet (106 mg elemental iron)</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td>150 mg tablet elemental iron</td>
<td>$1.37–$2.39 for 100 tablets</td>
</tr>
<tr>
<td>Ferrous gluconate</td>
<td>3–6 mg/kg/day</td>
<td>240 mg tablet (27 mg elemental iron)</td>
<td>$2.54 for 100 tablets</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 g tablet (37.5 mg elemental iron)</td>
<td>$2.54 for 100 tablets</td>
</tr>
<tr>
<td>Iron polysaccharide complex</td>
<td>3–6 mg/kg/day</td>
<td>100 mg elemental iron/5 mL</td>
<td>$4.05 for 118 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>150 mg elemental iron capsules</td>
<td>$7.05–$7.54 for 100 capsules</td>
</tr>
<tr>
<td>Parenteral</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iron dextran</td>
<td>10–100 mg/dose</td>
<td>50 mg elemental iron/mL</td>
<td>$226.76–$283.83 for 20 mL</td>
</tr>
<tr>
<td>Ferric dersomaltose</td>
<td>20 mg/kg/dose</td>
<td>100 mg elemental iron/mL</td>
<td>$1827.55–$2427.12 for 10 mL</td>
</tr>
<tr>
<td>Sodium ferric gluconate complex</td>
<td>1.5 mg/kg/dose</td>
<td>12.5 mg elemental iron/mL</td>
<td>$70.35 for 50 mL</td>
</tr>
<tr>
<td>Ferric carboxymaltose</td>
<td>15 mg/kg/dose</td>
<td>50 mg elemental iron/mL</td>
<td>$635.65 for 15 mL</td>
</tr>
<tr>
<td>Iron sucrose</td>
<td>5–7 mg/kg/dose</td>
<td>20 mg elemental iron/mL</td>
<td>$248.64–$257.20 for 50 mL</td>
</tr>
</tbody>
</table>

*Based on the Federal Supply Schedule.

TREATMENT OF ID IN IR

Several factors must be considered in determining the appropriate route of treatment for each child. In this section, we discuss the available methods of iron supplementation (Table 4) and unique considerations for children undergoing IR.

Dietary Enrichment

With many families looking to reduce medication burden, iron-rich food offers an alluring treatment option. No studies have examined the contribution of iron-rich foods to ID treatment in children undergoing IR. However, iron-rich food supplementation has been attempted in other clinical settings. In adult women with celiac disease, oral iron supplementation was superior to iron-rich diet; no participant in the iron-rich group successfully achieved goal iron intake (67). ID is less common in children who eat meat than in children who are vegetarian, perhaps due to absorption of iron through heme (68). In children undergoing IR, dietary treatments may have limited appeal as the high prevalence of feeding disorders and restricted diets may limit intake (41). However, in qualitative studies, some families whose children do have enteral tolerance have expressed a desire to pursue this option (69).

Recommendations: There is insufficient evidence to recommend a trial of dietary enrichment alone for the treatment of ID. Dietary enrichment may be used as an adjunct to supplementation. (8 authors in favor)

Enteral Supplementation

Oral and enteral iron supplementation carry many of the same benefits and challenges as dietary enrichment. Oral supplements are most commonly available as iron salts which can be administered in tablet or liquid suspension. The liquid formulations can be administered via gastrostomy tube. Oral supplementation traditionally occurs via the administration of ferrous sulfate, ferrous gluconate (FG), or ferrous fumarate. These formulations present low-cost, readily available options. The usual recommended dosing for prevention of ID is 3 mg/kg/day and for treatment of IDA is 4–6 mg/kg/day. As mentioned above, children undergoing IR may require higher than the generally recommended dosing (4–6 mg/kg/day for prevention and as high as 10 mg/kg/day elemental iron for treatment). Some children undergoing IR have feeding difficulties or avoidant restrictive feeding disorders and experience symptom exacerbation with enteral iron. Issues with intolerance may be overcome by starting with a lower dose and gradually increasing the dose or diluting the dose with a diluent like water or oral rehydration solution before administration. Studies in adults have shown that increasing the dose of oral iron supplementation and dividing the dose into 2–3 doses increased serum hepcidin levels and reduced fractional iron absorption (70). This is hypothesized to worsen GI discomfort or tolerance through iron accumulation in the intestine. Therefore, the current suggestion to maximize absorption and minimize side effects favors once daily dosing. In some children, the GI side effects may preclude enteral iron therapy, regardless of dosing strategy.

Alternative iron formulations have aimed to address the GI side effects of iron supplementation. Iron polysaccharide complex (NovaFerrum, Gensavis Pharmaceuticals LLC, Greenville, SC) attempts to reduce side effects but may have decreased efficacy in correcting ID (71). Still, in children that may have significant GI symptoms at baseline, iron polysaccharide may provide a better tolerated, low osmolarity alternative for maintenance therapy and allow for higher dosing to improve efficacy. Dosing enteral iron daily to every other day may also improve tolerance and allow for improved absorption by capitalizing on the half-life and variable induction of hepcidin (72).

Parenteral Supplementation

There are currently 4 IV iron formulations that are U.S. Food and Drug Administration-approved for use in pediatrics: iron sucrose (IS), low molecular weight iron dextran (LMWID), ferric carboxymaltose (FCM), and FG. Of these, only LMWID and FCM are approved for children who do not have chronic kidney disease. These formulations differ in a few important ways. Initial IV iron preparations, such as high molecular weight iron dextran, carried...
Iron Inclusive PN

The most recent American Society for Parenteral and Enteral Nutrition PN micronutrient consensus statement warns that clinicians should be aware of potential stability issues with iron supplementation within PN and states that the current preferred method of supplementation is oral/enteral administration or intermittent infusions (75,76). A recently published paper by Herdes et al (77) identified 5 major concerns with the addition of iron in PN; namely peroxidation reactions, incompatibility (with 3:1 solution), hypersensitivity, risk of infection, and risk of iron overload. Moreover, ferric and ferrous ions can neutralize the negative surface potential of lipid droplets, which can cause them to coalesce and fuse into large lipid droplets, causing issues with clogging lines and potentially leading to the development of fat embolism syndrome (78). Thus, many IR centers in the United States do not supplement iron in PN, favoring intermittent infusions when needed. However, recent guidelines on pediatric PN from the ESPGHAN/ESPEN/ESPR/CS/PEN working group on pediatric PN suggest parenteral iron may be added to PN, and tested for stability, when risks of intermittent infusions favor doing so (79). Further, a recent ESPEN micronutrient guideline recommends, by strong consensus, that in many circumstances PN shall provide at least 1 milligram of iron overload. Moreover, ferric and ferrous ions can neutralize the negative surface potential of lipid droplets, which can cause them to coalesce and fuse into large lipid droplets, causing issues with clogging lines and potentially leading to the development of fat embolism syndrome (78). Thus, many IR centers in the United States do not supplement iron in PN, favoring intermittent infusions when needed. However, recent guidelines on pediatric PN from the ESPGHAN/ESPEN/ESPR/CS/PEN working group on pediatric PN suggest parenteral iron may be added to PN, and tested for stability, when risks of intermittent infusions favor doing so (79). Further, a recent ESPEN micronutrient guideline recommends, by strong consensus, that in many circumstances PN shall provide at least 1 milligram per day of elemental iron when not dosed at periodic interval by separate infusions (80). In summary, though addition of iron to PN is not routinely practiced in the United States, it is common elsewhere.

Choosing the Right Supplementation

Choosing the best treatment among the available oral and IV options can be challenging. A patient-specific approach is recommended. This begins with the classification of each child’s degree of ID as previously defined. Next, the clinician must consider the methods of suitable administration for the individual.

1. **Children without ID**: Children undergoing IR should be provided iron supplementation when daily iron intake through food or formula falls short of approximate RDA. In those with enteral tolerance, and without a family history of hemochromatosis, enteral iron supplementation should be used. Children exclusively receiving PN without enteral feeding can only receive iron supplementation parenterally. To balance the risks of iron overload with the benefits of scheduled IV supplementation, iron status should be carefully monitored and IV iron only be supplemented when there is evidence of ID.

   **Recommendation**: In children undergoing IR without ID, we recommend enteral supplementation or IV supplementation in those who have minimal enteral intake, along with monitoring (every 3–6 months) for the development of ID or iron overload. (7 authors in favor, 1 opposed)

2. **Children with ID without anemia**: Children with ID in the absence of anemia should undergo enteral iron supplementation to replete iron stores. Enteral iron repletion can lead to GI symptoms that may not only limit adherence but also may exacerbate oral aversive behaviors. While a therapeutic trial of enteral iron repletion is still recommended, careful consideration must be given to the child’s stage of oral and IR and to how enteral iron use could affect this progress. Among children undergoing IR lacking enteral tolerance or among those failing enteral iron, parenteral supplementation may be needed. This is most commonly provided as intermittent iron infusions, given no more frequently than monthly. Intermittent, IV infusions may also be needed in a minority of children who have already achieved enteral autonomy when enteral intolerance or ineffectiveness occurs, or when the iron deficit is high due to age and intake needs.

   **Recommendation**: In children undergoing IR with ID without anemia, we recommend enteral iron if tolerated and parenteral iron only in those without enteral tolerance or in children who are unresponsive to enteral supplementation. (7 authors in favor, 1 abstained)

3. **Children with iron deficiency anemia**: Children with IDA require iron replacement. The iron replacement dose may be calculated using the formula $60 \times \text{weight} (\text{kg}) \times \text{[(target Hb – current Hb)/target Hb]}$. The typical target Hb is set at 12 g/dL, although a lower number (10 g/dL) may be appropriate in children undergoing IR to avoid iron overload. Among those with enteral tolerance, enteral repletion is recommended. In the absence of tolerance, optimal enteral treatment effect, or adherence, replacement should be provided IV. Care should be taken in choosing an appropriate formulation to best fit the needs of the individual child. Formulations in which a single, high replacement dose can be provided rather than multiple infusions to reach a replacement target are preferred. IV iron is often used to correct any iron deficit prior to initiating enteral iron maintenance therapy. In those with a Hb of <8 g/dL with evidence of IDA and no symptoms, we recommend enteral therapy prior to trial of IV iron. In children with a Hb of <8 g/dL with laboratory evidence of IDA, we recommend IV iron irrespective of symptoms if anemia. Packed RBC transfusions are reserved for those with symptomatic anemia and are intentionally limited in those with a potential need for future organ transplantation.

   **Recommendation**: In children undergoing IR with IDA, we recommend parenteral iron to replace any iron deficit followed by enteral or parenteral iron maintenance (via intermittent infusions) as appropriate for the individual child. We recommend assessing treatment response every 1–3 months. (8 authors in favor)

Cost considerations may also affect the decision of iron supplementation. A limited decision analysis performed using data from a single-center cohort of children with IF suggested that enteral supplementation was superior to no supplementation at reducing transfusion requirements. Enteral supplementation was also cost-effective compared to IV supplementation. However, the analysis was limited to the acquisition and administration costs of blood transfusions. Not considered was the effect of increased blood transfusions on quality of life and outcomes, especially in sensitizing children who may need transplant. The analysis only considered ferrous sulfate and iron sucrose; other iron formulations may affect this result (81).
Monitoring While Receiving Treatment and Preventing Iron Overload

Monitoring of children with IF during iron supplementation must focus on both successful ID treatment and the avoidance of complications. As discussed previously, no single index sufficiently describes the iron status of a particular child. If treatment is initiated due to biochemical evidence of ID, monitoring should include routine assessment of Hb and iron indices including SF and TSAT. For those presenting with severe IDA, evaluation of the response to treatment will typically need to occur 1 month after treatment completion. For those with a milder presentation or ID without anemia, monitoring may occur at the frequency of other micronutrient monitoring, typically every 3–6 months. Serum hepcidin can be considered in children in whom the diagnosis of ID is unclear and there is a necessity to rule out anemia of inflammation.

Recommendation: In children undergoing IR with ID without IDA, we recommend assessing response to treatment every 3–6 months. (8 authors in favor)

Recommendation: In children undergoing IR with IDA, we recommend assessing response to treatment every 1–3 months. (8 authors in favor)

In addition to monitoring for response to therapy, monitoring for complications of iron therapy must be considered. In particular, in those on IV supplementation, or in those with underlying hemochromatosis, iron overload can occur, leading to infection, hepatotoxicity, cardiotoxicity, or endocrine abnormalities (30,31). Liver enzymes and platelet counts are monitored routinely in this population as IFALD has been well-described. Monitoring for potential cardiac or endocrine abnormalities may occur based on TSAT, concerning history or physical exam.

Finally, as discussed earlier, non-transferrin bound iron can increase risk of infection. Many microorganisms (E coli, Klebsiella, Pseudomonas, Salmonella) use unbound iron to enhance their growth (20,22,23,82–85). Increased serum iron concentration can also impair polymorphonuclear cell phagocytosis, inhibiting bactericidal activity and increasing the risk for infection and sepsis in children already at high risk (21,85). Despite these risks, cross-sectional studies of adults on hemodialysis suggest low adverse drug event rate (86).

FUTURE DIRECTIONS

Prevalence of ID among children requiring IR and its potential consequences requires a firm grasp of present-day diagnostic and management strategies. Advancing care of this unique population demands improved recognition of the problem as well as improved efficacy of treatments and equity across care centers. Because IF is a rare and heterogeneous disorder, generalizable knowledge generation is nearly impossible from single-center study. The International Intestinal Failure Registry seeks to prospectively develop such generalizable knowledge to describe course and outcomes, which will be vital work in all facets of IF care with clear implications that will improve care for people with IF and SBS. Further, in the era of electronic health records, a multisite collaborative care using the learning health system model may be possible (87). Such an effort could provide a backbone for the future studies and support prospective quality improvement and patient partnership initiatives aiming to improve iron status across the population (88).

With a high prevalence by typical means of assessment, challenges include recognition of those in need of supplementation and in triaging discussions that require most attention during limited clinic time. These challenges are compounded by the population's complex health needs, disease-based intolerance of enteral medications, complex multi-organ pathophysiology, and generally large supplementation needs. A cross-sectional, multi-site survey of multiple iron indices of this population as associated with other important clinical variables would permit calibration of provider responsiveness and could be accomplished among centers with monitoring protocols backed by quality assurance programs in the near-term. An international multi-site registry could also assess the population level prevalence of ID in children with IF. Furthermore, such multi-site registries can help assessing different modalities used in prevention of ID (oral vs IV vs iron in PN) in this vulnerable population with key outcomes of interest including inflammation, oxidative stress, microbiome changes, and risk of central line associated bloodstream infection. There is also lack of data on the optimal frequency of phlebotomy that would be safe while monitoring PN labs and studies are needed to address these.

Finally, the gross deviation from typical GI physiology occurring in IF has also been associated with substantial dysbiosis. Characteristics of gut microbial community function and composition in IF have been studied with association to poor growth, ability to wean off PN, liver disease, and duration of intestinal adaptation (89,90). SBBO is a primary clinical disorder of IF dysbiosis characterized by a variety of nonspecific and semi-specific complaints and thought to occur with abnormally high concentrations of bacteria in the small bowel (91,92). In light of a large and growing body of literature suggesting an influence of ID and iron supplementation on microbial communities, as well as the theoretical potential for SBBO to create a high hepcidin state, clarity of the impact of this relationship as it specifically pertains to IF outcomes is an important near-term need in assembling a larger understanding of iron in IF (93,94).

CONCLUSIONS

ID is the most common and diagnostically challenging nutritional deficiencies in children undergoing IR. Multiple etiologies for deficiency may coexist, presently available laboratory assessment paradigms are flawed, and treatment approaches are varied. A firm understanding of underlying physiology and alignment of diagnostic and therapeutic approach across IR centers may support academic investigation and drive improvement in this important facet of care of this nutritionally vulnerable population.

Recommendations:

1. In children with suspected altered GI motility (gastroparisis, PIPO) or a history of gastrojejunal bypass, persistently draining G tube, we recommend clamping the G tube for 30 minutes after enteral iron administration into the gastric port for improved absorption into the duodenum.
2. Screening for ID/IDA in children undergoing IR should not be based on a Hb and MCV alone. We recommend screening for IDA based on CBC, SF, TSAT, serum iron concentration, and TIBC.
3. A CRP should be obtained while screening for ID as SF is an acute phase reactant.
4. Children undergoing IR should be screened for ID/IDA. We recommend screening every 3–6 months.
5. Vitamin B12, zinc, and copper deficiency should be evaluated based on anatomic risk and in children not responding to conventional treatment.
6. While assessing iron status in children undergoing IR, we recommend categorizing children into 3 categories: A. Children without ID; B. Children with ID without anemia; and C. Children with IDA. This will enable IR providers to make an informed decision regarding treatment.
7. Screening for thalassemia should be considered in children not responding to conventional treatment in certain patient populations.

8. In the assessment of ID in children undergoing IR, endoscopy is not routinely recommended. It can be considered if there is a poor response to enteral iron or if concerning signs and symptoms suggest GI bleeding, or intestinal inflammation.

9. Referral to a hematologist can be reserved for lack of recovery of Hb with iron supplementation, presence of pancytopenia, or difficulty distinguishing between multiple micronutrient deficiencies, portal hypertension, cancer, or other marrow insufficiency.

10. There is insufficient evidence to recommend a trial of dietary enrichment alone for the treatment of ID. Dietary enrichment may be used as an adjunct to supplementation.

11. In children undergoing IR without ID, we recommend enteral supplementation or IV supplementation in those who have minimal enteral intake, along with monitoring (every 3–6 months) for the development of ID or iron overload.

12. In children undergoing IR with ID without anemia, we recommend enteral iron if tolerated and parenteral iron only in those without enteral tolerance or in children who are unresponsive to enteral supplementation.

13. In children undergoing IR with IDA, we recommend parenteral iron to replace any iron deficit followed by enteral or parenteral iron maintenance (via intermittent infusions) as appropriate for the individual child. We recommend assessing treatment response every 1–3 months.

14. In children undergoing IR without IDA, we recommend assessing response to treatment every 3–6 months.

15. In children undergoing IR with IDA, we recommend assessing response to treatment every 1–3 months.

Acknowledgments: This paper was supported by NASPGHAN Intestinal Rehabilitation Special Interest Group and Tomas Ganz MD, PhD, Rachel Herdes DO, Elizabetha Nemeth PhD, Laurie Reyen MSN, CNS, and Jeffrey Rudolph MD.

REFERENCES


